Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis
Authors' conclusion
Compared with placebo, tirzepatide resulted in statistically significant and clinically meaningful weight reduction, especially in patients without diabetes (with overweight/obesity), with an acceptable safety profile.
Study context
- Population
- Adults with diabetes (BMI ≥ 23 kg/m²; 5 RCTs, n = 2,174) or without diabetes (BMI ≥ 27 [≥24 in Asia] kg/m²; 5 RCTs, n = 4,467), trials of ≥26 weeks10 RCTs
- Comparison
- Once-weekly tirzepatide vs placebo
- Outcome
- Relative and absolute weight reduction
- Follow-up
- At least 26 weeks
Methodological detailsrandom-effects model, stratified by diabetes status
- Random-effects model
- Stratified by diabetes status
Pooled result
As reported in the abstract
- With diabetes
- RR (relative weight reduction), with diabetes −9.54 %; P < 0.01
- With diabetes
- MD (absolute weight), with diabetes −9.06 kg; P < 0.01
- Without diabetes
- RR (relative weight reduction), without diabetes −17.15 %; P < 0.01
- Without diabetes
- MD (absolute weight), without diabetes −18.11 kg; P < 0.01
Further pooled results
- In both subpopulations, tirzepatide significantly increased the probability of ≥5%, ≥10% and ≥15% weight reduction and improved BMI, waist circumference, blood pressure, HbA1c and lipids
Safety
- Safety similar across subpopulations; predominantly mild to moderate, well-tolerated adverse events
Original publication
Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis. Int J Obes (Lond). Published 27 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →